Cellectar Narrows Losses 61% Amid Cash Burn, Going Concern Doubts

TL;DR

**Cellectar's deep cost cuts are a red flag, signaling a desperate scramble for cash that makes it a high-risk bet for traders.**

AI Summary

Cellectar Biosciences, Inc. (CLRB) reported a significant decrease in net loss for the nine months ended September 30, 2025, narrowing to $16,495,816 from $42,226,073 in the prior year, a 60.9% improvement. This was primarily driven by a substantial reduction in operating expenses, with research and development (R&D) costs falling 58.1% to $8,340,200 from $19,927,019, and general and administrative (G&A) expenses decreasing 53.1% to $8,949,015 from $19,105,853. The company's cash and cash equivalents significantly declined to $12,554,289 as of September 30, 2025, from $23,288,607 at December 31, 2024. Despite a net decrease in cash of $10,734,318, financing activities provided $8,039,763, including $5,788,380 from the issuance of common stock and pre-funded warrants. The company faces substantial doubt about its ability to continue as a going concern, with only $15.6 million in unrestricted cash and cash equivalents to fund operations beyond Q3 2026, necessitating additional outside capital or strategic transactions.

Why It Matters

This filing reveals Cellectar Biosciences is significantly cutting costs, particularly in R&D, which could impact the pace of its drug development pipeline, including iopofosine I 131 and CLR 121225. For investors, the substantial doubt about the company's going concern status and limited liquidity of $15.6 million are critical, signaling potential dilution from future equity raises or a need for a strategic transaction. Employees face uncertainty regarding job security if cost-saving measures intensify or if the company fails to secure additional funding. In the competitive biopharmaceutical landscape, Cellectar's financial constraints could hinder its ability to compete with larger, better-funded rivals in bringing its Phospholipid Drug Conjugates (PDC) to market, affecting potential future customers.

Risk Assessment

Risk Level: high — The company explicitly states "These uncertainties raise substantial doubt about the Company's ability to continue as a going concern." As of September 30, 2025, Cellectar had only $12,554,289 in cash and cash equivalents, and projects only $15.6 million in unrestricted cash to fund operations beyond Q3 2026, indicating a severe liquidity crunch.

Analyst Insight

Investors should exercise extreme caution and consider divesting, given the explicit going concern warning and significant cash burn. New investors should avoid CLRB until the company demonstrates a clear path to sustainable funding or a successful strategic transaction, as substantial dilution or even bankruptcy are significant risks.

Financial Highlights

total Assets

$14,627,590

total Debt

$5,248,261

net Income

-$16,495,816

eps

-$7.82

cash Position

$12,554,289

Key Numbers

• $16,495,816 — Net Loss (for the nine months ended September 30, 2025, a 60.9% decrease from $42,226,073 in 2024)
• $8,340,200 — Research and Development Expenses (for the nine months ended September 30, 2025, a 58.1% decrease from $19,927,019 in 2024)
• $8,949,015 — General and Administrative Expenses (for the nine months ended September 30, 2025, a 53.1% decrease from $19,105,853 in 2024)
• $12,554,289 — Cash and Cash Equivalents (as of September 30, 2025, down from $23,288,607 at December 31, 2024)
• $15.6 million — Available Liquidity (to fund operations over the next twelve months beyond the issuance date)
• $263,838,000 — Accumulated Deficit (as of September 30, 2025)
• 4,240,134 — Shares of Common Stock Outstanding (as of November 10, 2025)
• $8,039,763 — Cash Provided by Financing Activities (for the nine months ended September 30, 2025)

Key Players & Entities

• Cellectar Biosciences, Inc. (company) — registrant
• NASDAQ Capital Market (regulator) — exchange for common stock
• U.S. SECURITIES AND EXCHANGE COMMISSION (regulator) — filing authority
• iopofosine I 131 (product) — product candidate
• CLR 121225 (product) — product candidate
• Phospholipid Drug Conjugates (product) — proprietary delivery platform
• Florham Park, New Jersey (location) — principal executive offices

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has substantial doubt about its ability to continue as a going concern. As of September 30, 2025, unrestricted cash and cash equivalents were $15.6 million, which is projected to fund operations only beyond Q3 2026. This necessitates securing additional outside capital or engaging in strategic transactions.
• Significant Cash Burn [high — financial]: Cash and cash equivalents decreased by $10,734,318 for the nine months ended September 30, 2025, to $12,554,289. While financing activities provided $8,039,763, the net decrease highlights the ongoing need for capital to sustain operations.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $263,838,000 as of September 30, 2025. This substantial deficit indicates a history of net losses and a significant reliance on external funding to cover operational costs.
• Reduced R&D and G&A Spending [medium — operational]: Research and development expenses decreased by 58.1% to $8,340,200, and general and administrative expenses fell by 53.1% to $8,949,015 for the nine months ended September 30, 2025. While this reduced the net loss, it may impact future product development and operational capacity.
• Warrant Liability and Valuation Fluctuations [medium — financial]: The company had a warrant liability of $801,650 as of September 30, 2025, down from $1,718,000 at December 31, 2024. Fluctuations in warrant valuation contributed $455,874 to other income for the nine months ended September 30, 2025, indicating potential volatility.

Industry Context

Cellectar Biosciences operates in the highly competitive biotechnology sector, focusing on developing targeted therapies. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies like Cellectar often rely on substantial external funding to advance their pipelines through clinical trials.

Regulatory Implications

As a biotechnology company, Cellectar is subject to rigorous oversight by regulatory bodies such as the FDA. Successful development and commercialization of its therapies depend on navigating complex clinical trial processes and obtaining regulatory approval, which carries significant time and financial risks.

What Investors Should Do

1. Monitor cash runway and future financing activities closely.
2. Evaluate the impact of reduced R&D and G&A spending.
3. Analyze the terms and potential dilution from recent financing.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported a significantly reduced net loss of $16,495,816, driven by substantial cuts in R&D and G&A expenses. Cash and cash equivalents stood at $12,554,289.
• 2024-12-31: As of December 31, 2024 — Cash and cash equivalents were $23,288,607, and total liabilities were $9,797,343.

Glossary

Going Concern

An accounting assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (The company explicitly states substantial doubt about its ability to continue as a going concern, highlighting a significant financial risk.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, less any cumulative net income. It represents a negative balance in retained earnings. (Cellectar has a substantial accumulated deficit of $263,838,000, indicating a long history of unprofitability.)

Pre-funded Warrants

A type of warrant that allows the holder to purchase shares at a nominal price, effectively acting as a pre-paid share. It is often used in financing rounds to avoid immediate dilution. (Mentioned as a source of financing, indicating the company is using equity instruments to raise capital.)

Diluted EPS

Earnings per share calculated after accounting for all dilutive securities, such as stock options, warrants, and convertible preferred stock. (The diluted EPS of -$7.82 for the nine months ended September 30, 2025, reflects the potential impact of outstanding dilutive securities on profitability per share.)

Mezzanine Equity

A hybrid form of capital that has characteristics of both debt and equity. In this filing, Series D preferred stock is classified as mezzanine equity. (The presence of Series D preferred stock ($1,382,023) indicates a layer of capital with specific rights and preferences.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Cellectar Biosciences significantly reduced its net loss by 60.9% to $16,495,816 compared to $42,226,073 in the prior year. This improvement was driven by a substantial decrease in operating expenses, with R&D costs down 58.1% and G&A expenses down 53.1%. However, cash and cash equivalents declined by $10,734,318 to $12,554,289, and the company continues to face going concern risks, despite raising $8,039,763 through financing activities.

Key Financial Figures

• $0.00001 — ch registered Common stock, par value $0.00001 CLRB NASDAQ Capital Market Indica

Filing Documents

• clrb-20250930x10q.htm (10-Q) — 1391KB
• clrb-20250930xex31d1.htm (EX-31.1) — 11KB
• clrb-20250930xex31d2.htm (EX-31.2) — 11KB
• clrb-20250930xex32d1.htm (EX-32.1) — 9KB
• 0001104659-25-110827.txt ( ) — 5706KB
• clrb-20250930.xsd (EX-101.SCH) — 39KB
• clrb-20250930_cal.xml (EX-101.CAL) — 35KB
• clrb-20250930_def.xml (EX-101.DEF) — 176KB
• clrb-20250930_lab.xml (EX-101.LAB) — 303KB
• clrb-20250930_pre.xml (EX-101.PRE) — 259KB
• clrb-20250930x10q_htm.xml (XML) — 908KB

Forward-Looking Statements

Forward-Looking Statements 3

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 5 Item 1.

Financial Statements

Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 4.

Controls and Procedures

Controls and Procedures 32

OTHER INFORMATION

PART II. OTHER INFORMATION 35 Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 6. Exhibits 37 Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This quarterly report on Form 10-Q of Cellectar Biosciences, Inc. (the "Company", "Cellectar", "we", "us", "our") contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. Examples of our forward-looking statements include: our current views with respect to our business strategy, business plan and research and development activities; the progress of our product development programs, including clinical testing and the timing of commencement and results thereof; our projected operating results, including research and development expenses; our ability to identify a strategic partner with the resources to develop iopofosine I 131 (also known as iopofosine or CLR 131) or otherwise continue the development or pursue other strategic options in connection with iopofosine ; our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise; our ability to initiate a Phase 1 imaging and dose escalation safety study for CLR 121225 (CLR 125) and obtain the necessary additional funding for such study; our ability to initiate a Phase 1b dose finding study for CLR 125 and obtain the necessary additional funding for such study; our ability to continue development plans for our clinical and preclinical assets; our ability to continue development plans for our Phospholipid Drug Conjugates (PDC); our ability to advance our technologies into product candidates; our ability to maintain orphan drug designation in the U.S. for iopofosine as a therapeutic for the treatment of multiple myeloma, neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma and lymphoplasmacytic lymphoma//Waldenstrom macroglobulinemia, and the expected benefits of orphan drug status; any disruptions to our suppliers; our current view regarding general economic and market conditions, including our competitiv

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CELLECTAR BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) September 30, December 31, 2025 2024 ASSETS CURRENT ASSETS: Cash and cash equivalents $ 12,554,289 $ 23,288,607 Prepaid expenses and other current assets 1,067,409 961,665 Total current assets 13,621,698 24,250,272 Property, plant & equipment, net 595,271 757,121 Operating lease right-of-use asset 380,841 436,874 Other long-term assets 29,780 29,780 TOTAL ASSETS $ 14,627,590 $ 25,474,047 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accrued liabilities $ 4,014,682 $ 7,585,340 Warrant liability 801,650 1,718,000 Lease liability, current 96,034 84,417 Total current liabilities 4,912,366 9,387,757 Lease liability, net of current portion 335,895 409,586 TOTAL LIABILITIES 5,248,261 9,797,343 COMMITMENTS AND CONTINGENCIES (Note 7) MEZZANINE EQUITY: Series D preferred stock, 111.11 shares authorized, issued and outstanding as of September 30, 2025 and December 31, 2024 1,382,023 1,382,023 STOCKHOLDERS' EQUITY: Series E-2 preferred stock, 1,225 shares authorized; 35.60 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 520,778 520,778 Common stock, $ 0.00001 par value; 170,000,000 shares authorized; 3,192,040 and 1,535,996 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 32 15 Additional paid-in capital 271,314,776 261,116,351 Accumulated deficit ( 263,838,280 ) ( 247,342,463 ) Total stockholders' equity 7,997,306 14,294,681 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 14,627,590 $ 25,474,047 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Table of Contents CELLECTAR BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Three Months Ended Sept

View Full Filing

View this 10-Q filing on SEC EDGAR